Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 142


Monoclonal Antibody Targeting Sialyl-di-Lewisa-Containing Internalizing and Noninternalizing Glycoproteins with Cancer Immunotherapy Development Potential.

Tivadar ST, McIntosh RS, Chua JX, Moss R, Parsons T, Zaitoun AM, Madhusudan S, Durrant LG, Vankemmelbeke M.

Mol Cancer Ther. 2020 Mar;19(3):790-801. doi: 10.1158/1535-7163.MCT-19-0221. Epub 2019 Dec 23.


Trastuzumab Deruxtecan in Previously Treated HER2-Positive Breast Cancer.

Modi S, Saura C, Yamashita T, Park YH, Kim SB, Tamura K, Andre F, Iwata H, Ito Y, Tsurutani J, Sohn J, Denduluri N, Perrin C, Aogi K, Tokunaga E, Im SA, Lee KS, Hurvitz SA, Cortes J, Lee C, Chen S, Zhang L, Shahidi J, Yver A, Krop I; DESTINY-Breast01 Investigators.

N Engl J Med. 2020 Feb 13;382(7):610-621. doi: 10.1056/NEJMoa1914510. Epub 2019 Dec 11.


PARP1 blockade is synthetically lethal in XRCC1 deficient sporadic epithelial ovarian cancers.

Ali R, Alabdullah M, Alblihy A, Miligy I, Mesquita KA, Chan SY, Moseley P, Rakha EA, Madhusudan S.

Cancer Lett. 2020 Jan 28;469:124-133. doi: 10.1016/j.canlet.2019.10.035. Epub 2019 Oct 24.


ATM Regulated PTEN Degradation Is XIAP E3 Ubiquitin Ligase Mediated in p85α Deficient Cancer Cells and Influence Platinum Sensitivity.

Ali R, Alabdullah M, Miligy I, Normatova M, Babaei-Jadidi R, Nateri AS, Rakha EA, Madhusudan S.

Cells. 2019 Oct 18;8(10). pii: E1271. doi: 10.3390/cells8101271.


ERCC1 Is a Predictor of Anthracycline Resistance and Taxane Sensitivity in Early Stage or Locally Advanced Breast Cancers.

Abdel-Fatah TMA, Ali R, Sadiq M, Moseley PM, Mesquita KA, Ball G, Green AR, Rakha EA, Chan SYT, Madhusudan S.

Cancers (Basel). 2019 Aug 10;11(8). pii: E1149. doi: 10.3390/cancers11081149.


Oncogenic osteomalacia and metastatic breast cancer: a case report and review of the literature.

Savva C, Adhikaree J, Madhusudan S, Chokkalingam K.

J Diabetes Metab Disord. 2019 Mar 22;18(1):267-272. doi: 10.1007/s40200-019-00398-y. eCollection 2019 Jun.


Dealing with statutory bodies under the Mental Healthcare Act 2017.

Prashanth NR, Abraham SE, Hongally C, Madhusudan S.

Indian J Psychiatry. 2019 Apr;61(Suppl 4):S717-S723. doi: 10.4103/psychiatry.IndianJPsychiatry_152_19. Review.


ERCC1-XPF deficiency is a predictor of olaparib induced synthetic lethality and platinum sensitivity in epithelial ovarian cancers.

Mesquita KA, Alabdullah M, Griffin M, Toss MS, Fatah TMAA, Alblihy A, Moseley P, Chan SYT, Rakha EA, Madhusudan S.

Gynecol Oncol. 2019 May;153(2):416-424. doi: 10.1016/j.ygyno.2019.02.014. Epub 2019 Feb 21.


Clinicopathological significance of ataxia telangiectasia-mutated (ATM) kinase and ataxia telangiectasia-mutated and Rad3-related (ATR) kinase in MYC overexpressed breast cancers.

Savva C, De Souza K, Ali R, Rakha EA, Green AR, Madhusudan S.

Breast Cancer Res Treat. 2019 May;175(1):105-115. doi: 10.1007/s10549-018-05113-8. Epub 2019 Feb 12.


Ramucirumab with cisplatin and fluoropyrimidine as first-line therapy in patients with metastatic gastric or junctional adenocarcinoma (RAINFALL): a double-blind, randomised, placebo-controlled, phase 3 trial.

Fuchs CS, Shitara K, Di Bartolomeo M, Lonardi S, Al-Batran SE, Van Cutsem E, Ilson DH, Alsina M, Chau I, Lacy J, Ducreux M, Mendez GA, Alavez AM, Takahari D, Mansoor W, Enzinger PC, Gorbounova V, Wainberg ZA, Hegewisch-Becker S, Ferry D, Lin J, Carlesi R, Das M, Shah MA; RAINFALL Study Group.

Lancet Oncol. 2019 Mar;20(3):420-435. doi: 10.1016/S1470-2045(18)30791-5. Epub 2019 Feb 1. Erratum in: Lancet Oncol. 2019 May;20(5):e242.


The mTOR downstream regulator (p-4EBP1) is a novel independent prognostic marker in ovarian cancer.

Alabdullah ML, Ahmad DA, Moseley P, Madhusudan S, Chan S, Rakha E.

J Obstet Gynaecol. 2019 May;39(4):522-528. doi: 10.1080/01443615.2018.1534091. Epub 2019 Feb 4.


Upper GI biopsies for adenocarcinoma - how many biopsies should endoscopists take?

Kaye P, Lindsay D, Madhusudan S, Vohra R, Catton J, Platt C, Ragunath K.

Histopathology. 2019 May;74(6):959-963. doi: 10.1111/his.13816. Epub 2019 Apr 1.


Targeting PARP1 in XRCC1-Deficient Sporadic Invasive Breast Cancer or Preinvasive Ductal Carcinoma In Situ Induces Synthetic Lethality and Chemoprevention.

Ali R, Al-Kawaz A, Toss MS, Green AR, Miligy IM, Mesquita KA, Seedhouse C, Mirza S, Band V, Rakha EA, Madhusudan S.

Cancer Res. 2018 Dec 15;78(24):6818-6827. doi: 10.1158/0008-5472.CAN-18-0633. Epub 2018 Oct 8.


Feasibility of Intravenous Iron Isomaltoside to Improve Anemia and Quality of Life During Palliative Chemotherapy for Esophagogastric Adenocarcinoma.

Ng O, Keeler B, Simpson JA, Madhusudan S, Brookes M, Acheson A.

Nutr Cancer. 2018 Oct;70(7):1106-1117. doi: 10.1080/01635581.2018.1504090. Epub 2018 Sep 10.


LY2495655, an antimyostatin antibody, in pancreatic cancer: a randomized, phase 2 trial.

Golan T, Geva R, Richards D, Madhusudan S, Lin BK, Wang HT, Walgren RA, Stemmer SM.

J Cachexia Sarcopenia Muscle. 2018 Oct;9(5):871-879. doi: 10.1002/jcsm.12331. Epub 2018 Jul 27.


The relationship of CDK18 expression in breast cancer to clinicopathological parameters and therapeutic response.

Barone G, Arora A, Ganesh A, Abdel-Fatah T, Moseley P, Ali R, Chan SY, Savva C, Schiavone K, Carmell N, Myers KN, Rakha EA, Madhusudan S, Collis SJ.

Oncotarget. 2018 Jun 29;9(50):29508-29524. doi: 10.18632/oncotarget.25686. eCollection 2018 Jun 29.


Circulating biomarkers during treatment in patients with advanced biliary tract cancer receiving cediranib in the UK ABC-03 trial.

Backen AC, Lopes A, Wasan H, Palmer DH, Duggan M, Cunningham D, Anthoney A, Corrie PG, Madhusudan S, Maraveyas A, Ross PJ, Waters JS, Steward WP, Rees C, McNamara MG, Beare S, Bridgewater JA, Dive C, Valle JW.

Br J Cancer. 2018 Jul;119(1):27-35. doi: 10.1038/s41416-018-0132-8. Epub 2018 Jun 21.


Targeting ataxia telangiectasia-mutated- and Rad3-related kinase (ATR) in PTEN-deficient breast cancers for personalized therapy.

Al-Subhi N, Ali R, Abdel-Fatah T, Moseley PM, Chan SYT, Green AR, Ellis IO, Rakha EA, Madhusudan S.

Breast Cancer Res Treat. 2018 Jun;169(2):277-286. doi: 10.1007/s10549-018-4683-4. Epub 2018 Feb 2.


Primary Esophagogastric Neuroendocrine Carcinoma: a Retrospective Study from the Nottingham Upper Gastrointestinal Cancer Center.

Savva C, Kaye P, Soomro I, Parsons SL, James E, Madhusudan S.

J Gastrointest Cancer. 2018 Mar;49(1):85-92. doi: 10.1007/s12029-017-0039-2. No abstract available.


Evaluation of CDK12 Protein Expression as a Potential Novel Biomarker for DNA Damage Response-Targeted Therapies in Breast Cancer.

Naidoo K, Wai PT, Maguire SL, Daley F, Haider S, Kriplani D, Campbell J, Mirza H, Grigoriadis A, Tutt A, Moseley PM, Abdel-Fatah TMA, Chan SYT, Madhusudan S, Rhaka EA, Ellis IO, Lord CJ, Yuan Y, Green AR, Natrajan R.

Mol Cancer Ther. 2018 Jan;17(1):306-315. doi: 10.1158/1535-7163.MCT-17-0760. Epub 2017 Nov 13.


RECQ1 expression is upregulated in response to DNA damage and in a p53-dependent manner.

Parvathaneni S, Lu X, Chaudhary R, Lal A, Madhusudan S, Sharma S.

Oncotarget. 2017 May 27;8(44):75924-75942. doi: 10.18632/oncotarget.18237. eCollection 2017 Sep 29.


Postoperative survival following perioperative MAGIC versus neoadjuvant OE02-type chemotherapy in oesophageal adenocarcinoma.

Reece-Smith AM, Saunders JH, Soomro IN, Bowman CR, Duffy JP, Kaye PV, Welch NT, Madhusudan S, Parsons SL.

Ann R Coll Surg Engl. 2017 May;99(5):378-384. doi: 10.1308/rcsann.2017.0024.


Vandetanib plus gemcitabine versus placebo plus gemcitabine in locally advanced or metastatic pancreatic carcinoma (ViP): a prospective, randomised, double-blind, multicentre phase 2 trial.

Middleton G, Palmer DH, Greenhalf W, Ghaneh P, Jackson R, Cox T, Evans A, Shaw VE, Wadsley J, Valle JW, Propper D, Wasan H, Falk S, Cunningham D, Coxon F, Ross P, Madhusudan S, Wadd N, Corrie P, Hickish T, Costello E, Campbell F, Rawcliffe C, Neoptolemos JP.

Lancet Oncol. 2017 Apr;18(4):486-499. doi: 10.1016/S1470-2045(17)30084-0. Epub 2017 Mar 2.


The role of adjuvant platinum-based chemotherapy in esophagogastric cancer patients who received neoadjuvant chemotherapy prior to definitive surgery.

Saunders JH, Bowman CR, Reece-Smith AM, Pang V, Dorrington MS, Mumtaz E, Soomro I, Kaye P, Madhusudan S, Parsons SL.

J Surg Oncol. 2017 Jun;115(7):821-829. doi: 10.1002/jso.24601. Epub 2017 Mar 2.


Clinical Impact of Tumor DNA Repair Expression and T-cell Infiltration in Breast Cancers.

Green AR, Aleskandarany MA, Ali R, Hodgson EG, Atabani S, De Souza K, Rakha EA, Ellis IO, Madhusudan S.

Cancer Immunol Res. 2017 Apr;5(4):292-299. doi: 10.1158/2326-6066.CIR-16-0195. Epub 2017 Mar 2.


DNA damage repair in breast cancer and its therapeutic implications.

Ali R, Rakha EA, Madhusudan S, Bryant HE.

Pathology. 2017 Feb;49(2):156-165. doi: 10.1016/j.pathol.2016.11.002. Epub 2016 Dec 26. Review.


Clinicopathological and Functional Significance of RECQL1 Helicase in Sporadic Breast Cancers.

Arora A, Parvathaneni S, Aleskandarany MA, Agarwal D, Ali R, Abdel-Fatah T, Green AR, Ball GR, Rakha EA, Ellis IO, Sharma S, Madhusudan S.

Mol Cancer Ther. 2017 Jan;16(1):239-250. doi: 10.1158/1535-7163.MCT-16-0290. Epub 2016 Nov 11.


Combined Use of Rituximab and Intravenous Immunoglobulin for Severe Autoimmune Cicatricial Conjunctivitis-An Interventional Case Series.

Steger B, Madhusudan S, Kaye SB, Stylianides A, Romano V, Maqsood SE, Harper J, Ahmad S.

Cornea. 2016 Dec;35(12):1611-1614. doi: 10.1097/ICO.0000000000001024.


Clinical and biological significance of RAD51 expression in breast cancer: a key DNA damage response protein.

Alshareeda AT, Negm OH, Aleskandarany MA, Green AR, Nolan C, TigHhe PJ, Madhusudan S, Ellis IO, Rakha EA.

Breast Cancer Res Treat. 2016 Aug;159(1):41-53. doi: 10.1007/s10549-016-3915-8. Epub 2016 Jul 27.


Quality of life, long-term survivors and long-term outcome from the ABC-02 study.

Bridgewater J, Lopes A, Palmer D, Cunningham D, Anthoney A, Maraveyas A, Madhusudan S, Iveson T, Valle J, Wasan H.

Br J Cancer. 2016 Apr 26;114(9):965-71. doi: 10.1038/bjc.2016.64.


Reply, Letter to the Editor - The impact of sarcopenia and myosteatosis on outcomes of unresectable pancreatic cancer or distal cholangiocarcinoma.

Rollins KE, Tewari N, Ackner A, Awwad A, Madhusudan S, Macdonald IA, Fearon KC, Lobo DN.

Clin Nutr. 2016 Jun;35(3):765-6. doi: 10.1016/j.clnu.2016.03.006. Epub 2016 Mar 17. No abstract available.


Human Helicase RECQL4 Drives Cisplatin Resistance in Gastric Cancer by Activating an AKT-YB1-MDR1 Signaling Pathway.

Mo D, Fang H, Niu K, Liu J, Wu M, Li S, Zhu T, Aleskandarany MA, Arora A, Lobo DN, Madhusudan S, Balajee AS, Chi Z, Zhao Y.

Cancer Res. 2016 May 15;76(10):3057-66. doi: 10.1158/0008-5472.CAN-15-2361. Epub 2016 Mar 24.


Camptothecin targets WRN protein: mechanism and relevance in clinical breast cancer.

Shamanna RA, Lu H, Croteau DL, Arora A, Agarwal D, Ball G, Aleskandarany MA, Ellis IO, Pommier Y, Madhusudan S, Bohr VA.

Oncotarget. 2016 Mar 22;7(12):13269-84. doi: 10.18632/oncotarget.7906.


MYC functions are specific in biological subtypes of breast cancer and confers resistance to endocrine therapy in luminal tumours.

Green AR, Aleskandarany MA, Agarwal D, Elsheikh S, Nolan CC, Diez-Rodriguez M, Macmillan RD, Ball GR, Caldas C, Madhusudan S, Ellis IO, Rakha EA.

Br J Cancer. 2016 Apr 12;114(8):917-28. doi: 10.1038/bjc.2016.46. Epub 2016 Mar 8.


RECQL4 helicase has oncogenic potential in sporadic breast cancers.

Arora A, Agarwal D, Abdel-Fatah TM, Lu H, Croteau DL, Moseley P, Aleskandarany MA, Green AR, Ball G, Rakha EA, Chan SY, Ellis IO, Wang LL, Zhao Y, Balajee AS, Bohr VA, Madhusudan S.

J Pathol. 2016 Mar;238(4):495-501. doi: 10.1002/path.4681. Epub 2016 Feb 2.


ATM, ATR and DNA-PKcs expressions correlate to adverse clinical outcomes in epithelial ovarian cancers.

Abdel-Fatah TM, Arora A, Moseley P, Coveney C, Perry C, Johnson K, Kent C, Ball G, Chan S, Madhusudan S.

BBA Clin. 2014 Aug 14;2:10-7. doi: 10.1016/j.bbacli.2014.08.001. eCollection 2014 Dec.


Clinicopathological and prognostic significance of RECQL5 helicase expression in breast cancers.

Arora A, Abdel-Fatah TM, Agarwal D, Doherty R, Croteau DL, Moseley PM, Hameed K, Green A, Aleskandarany MA, Rakha EA, Patterson K, Ball G, Chan SY, Ellis IO, Bohr VA, Bryant HE, Madhusudan S.

Carcinogenesis. 2016 Jan;37(1):63-71. doi: 10.1093/carcin/bgv163. Epub 2015 Nov 19.


Camptodactyly-arthropathy-coxa vara-pericarditis (CACP) syndrome: a mimicker of juvenile idiopathic arthritis.

Madhusudan S, Gupta A, Prakash M, Matta D, Suri D, Singh S.

Scand J Rheumatol. 2016 Jan;45(1):77-78. doi: 10.3109/03009742.2015.1085085. Epub 2015 Oct 28. No abstract available.


Chk1 phosphorylated at serine345 is a predictor of early local recurrence and radio-resistance in breast cancer.

Alsubhi N, Middleton F, Abdel-Fatah TM, Stephens P, Doherty R, Arora A, Moseley PM, Chan SY, Aleskandarany MA, Green AR, Rakha EA, Ellis IO, Martin SG, Curtin NJ, Madhusudan S.

Mol Oncol. 2016 Feb;10(2):213-23. doi: 10.1016/j.molonc.2015.09.009. Epub 2015 Oct 3.


The impact of sarcopenia and myosteatosis on outcomes of unresectable pancreatic cancer or distal cholangiocarcinoma.

Rollins KE, Tewari N, Ackner A, Awwad A, Madhusudan S, Macdonald IA, Fearon KC, Lobo DN.

Clin Nutr. 2016 Oct;35(5):1103-9. doi: 10.1016/j.clnu.2015.08.005. Epub 2015 Sep 1.


5-Carboxylcytosine levels are elevated in human breast cancers and gliomas.

Eleftheriou M, Pascual AJ, Wheldon LM, Perry C, Abakir A, Arora A, Johnson AD, Auer DT, Ellis IO, Madhusudan S, Ruzov A.

Clin Epigenetics. 2015 Aug 21;7:88. doi: 10.1186/s13148-015-0117-x. eCollection 2015.


DNA repair prognostic index modelling reveals an essential role for base excision repair in influencing clinical outcomes in ER negative and triple negative breast cancers.

Abdel-Fatah TM, Arora A, Moseley PM, Perry C, Rakha EA, Green AR, Chan SY, Ellis IO, Madhusudan S.

Oncotarget. 2015 Sep 8;6(26):21964-78.


Cediranib or placebo in combination with cisplatin and gemcitabine chemotherapy for patients with advanced biliary tract cancer (ABC-03): a randomised phase 2 trial.

Valle JW, Wasan H, Lopes A, Backen AC, Palmer DH, Morris K, Duggan M, Cunningham D, Anthoney DA, Corrie P, Madhusudan S, Maraveyas A, Ross PJ, Waters JS, Steward WP, Rees C, Beare S, Dive C, Bridgewater JA.

Lancet Oncol. 2015 Aug;16(8):967-78. doi: 10.1016/S1470-2045(15)00139-4. Epub 2015 Jul 12. Erratum in: Lancet Oncol. 2015 Sep;16(9):e427.


KPNA2 is a nuclear export protein that contributes to aberrant localisation of key proteins and poor prognosis of breast cancer.

Alshareeda AT, Negm OH, Green AR, Nolan CC, Tighe P, Albarakati N, Sultana R, Madhusudan S, Ellis IO, Rakha EA.

Br J Cancer. 2015 Jun 9;112(12):1929-37. doi: 10.1038/bjc.2015.165. Epub 2015 May 19.


Transcriptomic profiling of Forkhead box transcription factors in adult glioblastoma multiforme.

Robertson E, Perry C, Doherty R, Madhusudan S.

Cancer Genomics Proteomics. 2015 May-Jun;12(3):103-12.


DNA Repair Endonucleases: Physiological Roles and Potential as Drug Targets.

Doherty R, Madhusudan S.

J Biomol Screen. 2015 Aug;20(7):829-41. doi: 10.1177/1087057115581581. Epub 2015 Apr 15. Review.


Monoclonal Antibodies Targeting LecLex-Related Glycans with Potent Antitumor Activity.

Chua JX, Vankemmelbeke M, McIntosh RS, Clarke PA, Moss R, Parsons T, Spendlove I, Zaitoun AM, Madhusudan S, Durrant LG.

Clin Cancer Res. 2015 Jul 1;21(13):2963-74. doi: 10.1158/1078-0432.CCR-14-3030. Epub 2015 Mar 16.


Checkpoint kinase1 (CHK1) is an important biomarker in breast cancer having a role in chemotherapy response.

Al-Kaabi MM, Alshareeda AT, Jerjees DA, Muftah AA, Green AR, Alsubhi NH, Nolan CC, Chan S, Cornford E, Madhusudan S, Ellis IO, Rakha EA.

Br J Cancer. 2015 Mar 3;112(5):901-11. doi: 10.1038/bjc.2014.576. Epub 2015 Feb 17.


Transcriptomic and Protein Expression Analysis Reveals Clinicopathological Significance of Bloom Syndrome Helicase (BLM) in Breast Cancer.

Arora A, Abdel-Fatah TM, Agarwal D, Doherty R, Moseley PM, Aleskandarany MA, Green AR, Ball G, Alshareeda AT, Rakha EA, Chan SY, Ellis IO, Madhusudan S.

Mol Cancer Ther. 2015 Apr;14(4):1057-65. doi: 10.1158/1535-7163.MCT-14-0939. Epub 2015 Feb 11.


Biological and clinical significance of PARP1 protein expression in breast cancer.

Green AR, Caracappa D, Benhasouna AA, Alshareeda A, Nolan CC, Macmillan RD, Madhusudan S, Ellis IO, Rakha EA.

Breast Cancer Res Treat. 2015 Jan;149(2):353-62. doi: 10.1007/s10549-014-3230-1. Epub 2014 Dec 21.

Supplemental Content

Loading ...
Support Center